Meeting
2015 ASCO Annual Meeting
Electronic medical record as a research tool: Virtual clinical trial comparing pemetrexed and gemcitabine, both given with cisplatin, in patients with lung adenocarcinomas.
Authors
Alexander Grigorenko
Memorial Sloan Kettering Cancer Center, New York, NY
Alexander Grigorenko , Paul May , Nicholas Kastango , Howard T. Thaler , Isaac Wagner , Aryeh Caroline , Mark G. Kris , Marjorie Glass Zauderer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8024)
DOI
10.1200/jco.2015.33.15_suppl.8024
Abstract #
8024
Poster Bd #
346
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
First Author: Patrick M. Forde
Poster
2011 ASCO Annual Meeting
Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).
First Author: H. A. Wakelee
Poster
2024 ASCO Genitourinary Cancers Symposium
Pemetrexed (PEM) maintenance versus observation (OBS) in patients (pts) with advanced urothelial carcinoma (aUC) who completed first-line (1L) platinum-based chemotherapy (CTx) without disease progression (PREMIER, KCSG GU16-05).
First Author: Inkeun Park
Poster
2023 ASCO Annual Meeting
An intelligent machine learning model for real-time early detection of undesirable cancer events: AIM2REDUCE.
First Author: Robert C. Grant